Celastrol alleviates SGLT2 inhibitor-induced diabetic hyperketonemia by inhibiting hepatic ketogenesis
Authors:
Preprint
Abstract
SGLT2 inhibitor (SGLT2i)-induced diabetic hyperketonemia is a life-threatening acute complication of diabetes. While Celastrol has been reported to exert beneficial effects on obesity; its potential role in ketogenesis remains unclear. In this study, Celastrol administration significantly attenuates the fasting-induced elevation of blood β-hydroxybutyrate. Moreover, a 7-day course of Celastrol (1 mg/kg/day) leads to reductions in body weight and fat mass. Mechanistically, Celastrol specifically downregulates HMGCS2 expression and suppressess hepatic ketogenesis through inhibiting PPARα expression in the short term (≤ 2 days). However, after prolonged treatment for 7 days, Celastrol modulates both PPARαand serum free fatty acids (FFAs) levels. Furthermore, anti-ketogenic effect of Celastrol is abolished in Ppar α□ / □ mice. Importantly, Celastrol effectively ameliorates SGLT2i-induced hyperketonemia. In summary, Celastrol curbs hepatic ketone overproduction in a PPARα-dependent manner, indicating its protective potential against SGLT2i-induced hyperketonemia.Keywords
Funding Information
- Natural Science Foundation of Beijing Municipality (7242094)
- National Key Research and Development Program of China (2022YFC2504003)
- National Key Research and Development Program of China (2022YFC2504002)
- Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
This publication has 43 references indexed in Scilit:
- Revealing a new target: Celastrol alleviates pulmonary fibrosis by inhibiting PCAFBioorganic Chemistry, 2025
- Oxyresveratrol and/or Dapagliflozin Attenuate Doxorubicin-Induced Nephrotoxicity via Modulation of PPAR-γ/Nrf-2/HO-1, NF-κB/TNF-α/Keap-1, and Bcl-2/Caspase-3/ATG-5 signaling pathways in ratsNaunyn-Schmiedeberg's Archives of Pharmacology, 2024
- Inhibition of the RXRA-PPARα-FABP4 signaling pathway alleviates vascular cellular aging by an SGLT2 inhibitor in an atherosclerotic mice modelScience China Life Sciences, 2024
- Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategiesBiomedicine & Pharmacotherapy, 2023
- A comprehensive review on celastrol, triptolide and triptonide: Insights on their pharmacological activity, toxicity, combination therapy, new dosage form and novel drug delivery routesBiomedicine & Pharmacotherapy, 2023
- Lansoprazole enhances the antidiabetic effect of dapagliflozin in fortified diet‐fed streptozotocin‐treated diabetic ratsJournal of Biochemical and Molecular Toxicology, 2020
- Dapagliflozin: A Review in Type 2 DiabetesDrugs, 2019
- Treatment of Obesity with CelastrolCell, 2015
- Isolation and Culture of Adult Mouse Hepatocytes2010
- Pleiotropic effects of fibratesCurrent Atherosclerosis Reports, 2005